/

Sociétés

Ad

Non vérifié

Aditxt, Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversSantéSanté Publique

58 communiqués de presse

Voir tous les communiqués de presse

19/03/2026

Science

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Santé

Oncologie

Marché du travail

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Source

Émetteur

1.00

0

13/03/2026

Événements

Marché financier

Science

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Santé

Oncologie

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Source

Émetteur

1.00

0

05/03/2026

Finance

Science

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Source

Émetteur

1.00

0

18/11/2025

Technique

Santé

Finance

Santé Publique

Associations/Professionnels

Oncologie

Science

Logiciels

Titres et actions

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta’s Planned IPO, And Evofem’s Plan to Regain a National Listing

Source

Émetteur

1.00

0

29/10/2025

Santé

Science

Industrie pharmaceutique

Biotechnologie

Finance

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Source

Émetteur

1.00

0

27/10/2025

Santé Publique

Vitrines/Shopping

Santé

Médecine - Divers

Industrie

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Source

Émetteur

1.00

0

25/08/2025

Santé

Hygiène alimentaire

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

Industrie

Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Source

Émetteur

1.00

0

11/08/2025

Associations/Professionnels

Santé

Biotechnologie

Marché du travail

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Source

Émetteur

1.00

0

29/07/2025

Biotechnologie

Santé

Oncologie

Titres et actions

Marché du travail

Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Source

Émetteur

1.00

0

24/07/2025

Oncologie

Santé

Vitrines/Shopping

Biotechnologie

Événements

Industrie

Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0